Lars Richter
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Interests
Lars Richter has a total of 82 co-authors. Here are the top co-authors by number of shared publications:
- Gerhard Franz Ecker
Division of Pharmaceutical Chemistry, Pharmacoinformatics Research Group, University of Vienna, Vienna, Austria
16 shared publications - Doris Schütz5 shared publications
- Riccardo Martini5 shared publications
- Sophie Gugerell5 shared publications
- Margot Ernst
Department for Pathobiology of the Nervous System, Medical University of Vienna, Spitalgasse 4, A-1090, Vienna, Austria
4 shared publications - Barbara Zdrazil
European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Hinxton, UK
2 shared publications
Latest Publications
- Open Access
- 21 September 2020
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 11 (11) , 1285-1294
A structure–kinetic relationship study using matched molecular pair analysis
A large-scale study employing matched molecular pair (MMP) analysis to uncover the contribution of a compound's polarity to its association and dissociation rates.
- 21 September 2020
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 11 (11) , 1285-1294
Open AccessA structure–kinetic relationship study using matched molecular pair analysis
A large-scale study employing matched molecular pair (MMP) analysis to uncover the contribution of a compound's polarity to its association and dissociation rates.
- 20 July 2018
- Published by American Chemical Society (ACS) in Journal of Chemical Information and Modeling
- Vol. 58 (8) , 1682-1696
SAR-Guided Scoring Function and Mutational Validation Reveal the Binding Mode of CGS-8216 at the α1+/γ2– Benzodiazepine Site
The structural resolution of a bound ligand-receptor complex is a key asset to efficiently drive lead optimization in drug design. However, structural resolution of many drug targets still remains a challenging endeavor. In the absence of structural knowledge, scientists resort on structure-activity relationship (SAR) to promote compound development. In this study we incorporated ligand-based knowledge to formulate a docking scoring function which evaluates binding poses for their agreement with known SAR. We showcased this protocol by identifying the binding mode of the pyrazoloquinolinone (PQ) CGS-8216 at the benzodiazepine binding site of the GABAA receptor. Further evaluation of the final pose by molecular dynamics and free energy simulations revealed a close proximity between PQ’s pending phenyl ring and γ2D56 congruent with the low potency of carboxy-phenyl analogues. Ultimately, we introduced the γ2D56A mutation and in fact observed an 10-fold potency increase in the carboxy-phenyl analogue, providing experimental evidence in favour of our binding hypothesis.
- 20 July 2018
- Published by American Chemical Society (ACS) in Journal of Chemical Information and Modeling
- Vol. 58 (8) , 1682-1696
SAR-Guided Scoring Function and Mutational Validation Reveal the Binding Mode of CGS-8216 at the α1+/γ2– Benzodiazepine Site
The structural resolution of a bound ligand-receptor complex is a key asset to efficiently drive lead optimization in drug design. However, structural resolution of many drug targets still remains a challenging endeavor. In the absence of structural knowledge, scientists resort on structure-activity relationship (SAR) to promote compound development. In this study we incorporated ligand-based knowledge to formulate a docking scoring function which evaluates binding poses for their agreement with known SAR. We showcased this protocol by identifying the binding mode of the pyrazoloquinolinone (PQ) CGS-8216 at the benzodiazepine binding site of the GABAA receptor. Further evaluation of the final pose by molecular dynamics and free energy simulations revealed a close proximity between PQ’s pending phenyl ring and γ2D56 congruent with the low potency of carboxy-phenyl analogues. Ultimately, we introduced the γ2D56A mutation and in fact observed an 10-fold potency increase in the carboxy-phenyl analogue, providing experimental evidence in favour of our binding hypothesis.
- 27 April 2018
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 61 (10) , 4397-4411
Ligand Desolvation Steers On-Rate and Impacts Drug Residence Time of Heat Shock Protein 90 (Hsp90) Inhibitors
Residence time - and more recently - the association rate constant kon are increasingly acknowledged as important parameters for in vivo efficacy and safety of drugs. However, their broader consideration in drug development is limited by a lack of knowledge how to optimize these parameters. In this study on a set of 176 heat shock protein 90 inhibitors, Structure-Kinetic relationships, X-ray crystallography and Molecular Dynamics simulations were combined to retrieve a concrete scheme how to rationally slow down on-rates. We discovered that an increased ligand desolvation barrier by introducing polar substituents resulted in a significant kon decrease. The slowdown was accomplished by introducing polar moieties to those parts of the ligand, which point towards a hydrophobic cavity. We validated this scheme by increasing polarity of three Hsp90 inhibitors and observed a 9-, 13- and 45-fold slowdown of on-rates and a 9-fold prolongation in residence time. This prolongation was driven by transition state destabilization rather than ground state stabilization.
- 27 April 2018
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 61 (10) , 4397-4411
Ligand Desolvation Steers On-Rate and Impacts Drug Residence Time of Heat Shock Protein 90 (Hsp90) Inhibitors
Residence time - and more recently - the association rate constant kon are increasingly acknowledged as important parameters for in vivo efficacy and safety of drugs. However, their broader consideration in drug development is limited by a lack of knowledge how to optimize these parameters. In this study on a set of 176 heat shock protein 90 inhibitors, Structure-Kinetic relationships, X-ray crystallography and Molecular Dynamics simulations were combined to retrieve a concrete scheme how to rationally slow down on-rates. We discovered that an increased ligand desolvation barrier by introducing polar substituents resulted in a significant kon decrease. The slowdown was accomplished by introducing polar moieties to those parts of the ligand, which point towards a hydrophobic cavity. We validated this scheme by increasing polarity of three Hsp90 inhibitors and observed a 9-, 13- and 45-fold slowdown of on-rates and a 9-fold prolongation in residence time. This prolongation was driven by transition state destabilization rather than ground state stabilization.
- 11 October 2017
- Published by American Chemical Society (ACS) in Journal of Chemical Information and Modeling
- Vol. 57 (10) , 2575-2583
Topliss Batchwise Schemes Reviewed in the Era of Open Data Reveal Significant Differences between Enzymes and Membrane Receptors
In 1977, John G. Topliss introduced the Topliss Batchwise Scheme, a straightforward nonmathematical procedure to assist medicinal chemists in optimizing the substitution pattern of a phenyl ring. Despite its long period of application, a thorough validation of this method has been missing so far. Here, we address this issue by gathering 129 congeneric series from the ChEMBL database, suitable to retrospectively assess the approach. Frequency analysis of Topliss’ schemes showed that the π, Es, σ, and −σ scheme occurred in 17, 20, 6, and 4 congeneric series, respectively. We observed a significant difference of π scheme frequency in enzymes versus membrane receptors, with 12 versus only 2 occurrences. Validation of Topliss schemes in potency optimization showed a remarkable performance increase after restricting the data set to analogue series tested solely against enzymes. In this setting, the Es and the π scheme were successful in 50% and 56% of the analogue series, respectively.
- 11 October 2017
- Published by American Chemical Society (ACS) in Journal of Chemical Information and Modeling
- Vol. 57 (10) , 2575-2583
Topliss Batchwise Schemes Reviewed in the Era of Open Data Reveal Significant Differences between Enzymes and Membrane Receptors
In 1977, John G. Topliss introduced the Topliss Batchwise Scheme, a straightforward nonmathematical procedure to assist medicinal chemists in optimizing the substitution pattern of a phenyl ring. Despite its long period of application, a thorough validation of this method has been missing so far. Here, we address this issue by gathering 129 congeneric series from the ChEMBL database, suitable to retrospectively assess the approach. Frequency analysis of Topliss’ schemes showed that the π, Es, σ, and −σ scheme occurred in 17, 20, 6, and 4 congeneric series, respectively. We observed a significant difference of π scheme frequency in enzymes versus membrane receptors, with 12 versus only 2 occurrences. Validation of Topliss schemes in potency optimization showed a remarkable performance increase after restricting the data set to analogue series tested solely against enzymes. In this setting, the Es and the π scheme were successful in 50% and 56% of the analogue series, respectively.
- Top Cited Papers
- 1 June 2017
- Published by Elsevier in Drug Discovery Today
- Vol. 22 (6) , 896-911
Kinetics for Drug Discovery: an industry-driven effort to target drug residence time
- 1 June 2017
- Published by Elsevier in Drug Discovery Today
- Vol. 22 (6) , 896-911
Top Cited PapersKinetics for Drug Discovery: an industry-driven effort to target drug residence time